Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E16.24 EPS (ttm)5.32 Insider Own2.46% Shs Outstand17.56M Perf Week0.40%
Market Cap1.55B Forward P/E15.59 EPS next Y5.54 Insider Trans-9.03% Shs Float17.52M Perf Month22.78%
Income96.34M PEG0.81 EPS next Q0.99 Inst Own93.50% Short Float4.90% Perf Quarter16.10%
Sales118.31M P/S13.12 EPS this Y-23.81% Inst Trans-0.32% Short Ratio4.55 Perf Half Y45.19%
Book/sh45.00 P/B1.92 EPS next Y19.47% ROA11.17% Short Interest0.86M Perf Year15.83%
Cash/sh17.29 P/C5.00 EPS next 5Y20.00% ROE13.26% 52W Range49.24 - 94.57 Perf YTD20.97%
Dividend Est.- P/FCF48.25 EPS past 5Y-13.18% ROI11.87% 52W High-8.64% Beta1.04
Dividend TTM- Quick Ratio19.51 Sales past 5Y-3.89% Gross Margin64.12% 52W Low75.47% ATR (14)2.70
Dividend Ex-DateJul 02, 2010 Current Ratio20.70 EPS Y/Y TTM290.26% Oper. Margin-1.18% RSI (14)63.76 Volatility2.61% 3.47%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-45.70% Profit Margin81.43% Recom1.20 Target Price116.80
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q103.66% Payout0.00% Rel Volume0.85 Prev Close84.91
Sales Surprise10.94% EPS Surprise43.88% Sales Q/Q-29.56% EarningsMay 07 AMC Avg Volume188.58K Price86.40
SMA207.97% SMA5012.72% SMA20026.72% Trades Volume160,609 Change1.75%
Date Action Analyst Rating Change Price Target Change
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
May-23-24 04:59PM
May-20-24 06:00AM
May-13-24 12:00PM
May-10-24 08:50AM
May-09-24 09:40AM
01:22PM Loading…
May-08-24 01:22PM
May-07-24 09:01PM
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
06:00PM Loading…
Apr-05-24 06:00PM
Apr-04-24 09:30AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
07:34AM Loading…
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
Jun-05-23 11:49AM
Jun-02-23 12:39PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
May-17-23 01:59PM
May-16-23 09:56AM
May-12-23 12:08PM
May-11-23 12:25PM
May-08-23 12:32PM
May-06-23 10:13AM
May-05-23 10:00AM
May-04-23 05:45PM
May-02-23 08:30PM
Apr-28-23 02:04PM
Apr-27-23 09:04AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Espinoza OctavioChief Financial OfficerMay 17 '24Option Exercise55.716,917385,34628,535May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 17 '24Sale86.665,156446,84423,379May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 16 '24Sale86.002,264194,71221,618May 17 07:59 PM
Espinoza OctavioChief Financial OfficerMay 15 '24Sale86.015,873505,14823,882May 17 07:59 PM
Korenberg Matthew EPresident & Chief OperatingMay 14 '24Sale85.1014,1581,204,91286,263May 15 07:34 PM
Korenberg Matthew EPresident & Chief OperatingMay 13 '24Sale84.543,440290,828100,421May 15 07:34 PM
Reardon AndrewChief Legal Officer &May 09 '24Option Exercise52.2710,000522,70032,205May 13 05:32 PM
Reardon AndrewChief Legal Officer &May 09 '24Sale83.0410,000830,44922,205May 13 05:32 PM
Gray Nancy RyanDirectorMay 09 '24Sale83.2093477,7135,633May 17 08:00 PM
Aryeh JasonDirectorApr 30 '24Option Exercise52.302,406125,83476,828May 02 06:07 PM
KOZARICH JOHN WDirectorApr 24 '24Option Exercise39.352,893113,84042,523Apr 26 06:35 PM
Davis Todd CChief Executive OfficerMar 25 '24Option Exercise57.3916,015919,147120,160Mar 27 05:47 PM
Aryeh JasonDirectorMar 05 '24Option Exercise39.352,893113,84074,422Mar 06 05:28 PM
Sabba Stephen LDirectorMar 05 '24Option Exercise0.002,893030,819Mar 07 01:27 PM
Sabba Stephen LDirectorMar 05 '24Sale74.301,893140,65028,926Mar 07 01:27 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Sale88.4614012,38429,755Feb 29 06:50 PM
Davis Todd CCHIEF EXECUTIVE OFFICERSep 22 '23Buy59.384,000237,52973,090Sep 25 04:44 PM